EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47
Authors:
- 27 March 2024
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (8) , 1186-1200
Abstract
No abstract availableKeywords
Funding Information
- Sun Yat-sen University Cancer Center
- National Natural Science Foundation of China (82241232)
- National Natural Science Foundation of China (82102872)
- National Natural Science Foundation of China (82173101)
- National Natural Science Foundation of China (82373262)
This publication has 36 references indexed in Scilit:
- Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic reviewCancer Treatment Reviews, 2023
- Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectivesActa Pharmaceutica Sinica B, 2022
- CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancerFrontiers of Medicine, 2022
- A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockadeJournal of Cancer Research and Clinical Oncology, 2022
- Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaCancer Immunology, Immunotherapy, 2021
- Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancerJournal of Cancer Research and Clinical Oncology, 2021
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerAnnals of Oncology, 2020
- Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancerCancer Medicine, 2020
- Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in miceHepatology, 2015